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Background: The prognostic role of tumor-related parameters in diffuse large B cell lymphoma (DLBCL) is a matter
of controversy.
Methods: We investigated the prognostic value of phenotypic and genotypic profiles in DLBCL in clinical trial
(NCT00544219) patients homogenously treated with six cycles of rituximab, cyclophosphamide, hydroxydaunorubicin,
vincristine, prednisone (R-CHOP), followed by two cycles of R (R-CHOP-14). The primary endpoint was event-free
survival at 2 years (EFS). Secondary endpoints were progression-free (PFS) and overall survival (OS). Immunohistochemical
(bcl2, bcl6, CD5, CD10, CD20, CD95, CD168, cyclin E, FOXP1, GCET, Ki-67, LMO2, MUM1p, pSTAT3) and in situ hybridization
analyses (BCL2 break apart probe, C-MYC break apart probe and C-MYC/IGH double-fusion probe, and Epstein–Barr virus
probe) were performed and correlated with the endpoints.
Results: One hundred twenty-three patients (median age 58 years) were evaluable. Immunohistochemical assessment
succeeded in all cases. Fluorescence in situ hybridization was successful in 82 instances. According to the Tally algorithm,
81 cases (66 %) were classified as non-germinal center (GC) DLBCL, while 42 cases (34 %) were GC DLBCL. BCL2 gene
breaks were observed in 7/82 cases (9 %) and C-MYC breaks in 6/82 cases (8 %). “Double-hit” cases with BCL2 and C-MYC
rearrangements were not observed. Within the median follow-up of 53 months, there were 51 events, including 16 lethal
events and 12 relapses. Factors able to predict worse EFS in univariable models were failure to achieve response
according to international criteria, failure to achieve positron emission tomography response (p < 0.005), expression
of CD5 (p = 0.02), and higher stage (p = 0.021). Factors predicting inferior PFS were failure to achieve response
according to international criteria (p < 0.005), higher stage (p = 0.005), higher International Prognostic Index (IPI;
p = 0.006), and presence of either C-MYC or BCL2 gene rearrangements (p = 0.033). Factors predicting inferior OS
were failure to achieve response according to international criteria and expression of FOXP1 (p < 0.005), cyclin E,
CD5, bcl2, CD95, and pSTAT3 (p = 0.005, 0.007, 0.016, and 0.025, respectively). Multivariable analyses revealed that
expression of CD5 (p = 0.044) and FOXP1 (p = 0.004) are independent prognostic factors for EFS and OS, respectively.
Conclusion: Phenotypic studies with carefully selected biomarkers like CD5 and FOXP1 are able to prognosticate
DLBCL course at diagnosis, independent of stage and IPI and independent of response to R-CHOP.
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Diffuse large B cell lymphoma (DLBCL) is the most
common nodal lymphoid malignancy, comprising ap-
proximately 30 % of all adult lymphomas, with a rapidly
rising incidence [1, 2]. DLBCL demonstrates an aggres-
sive clinical course, but potentially 60–70 % of patients
can be cured with the established rituximab, cyclophos-
phamide, hydroxydaunorubicin, vincristine, prednisone
(R-CHOP) treatment standard [3]. Prediction of survival
and stratification of patients for risk-adjusted therapy is
based on the International Prognostic Index (IPI) [4]. R-
CHOP has not only led to a marked improvement of
survival in DLBCL but has also called into question the
significance of the IPI [5], leading to introduction of the
revised IPI (R-IPI) [6]. Recent data suggests that IPI and
R-IPI no longer reliably identify DLBCL risk groups with
a <50 % chance of survival, despite about 30–40 % of
patients will still die of/with disease. Thus, there is a
need for additional, particularly tumor-related, prognostic
(and predictive) factors in DLBCL [7].
To date, only a limited number of tumor-related prog-
nostic parameters exist for DLBCL like presence of C-
MYC rearrangements or co-expression of bcl2 and c-myc.
The morphological heterogeneity of DLBCL is reflected
by significant molecular diversity at the genotypic, gene
expression, and phenotypic levels [8, 9]. Gene expression
profiling data convincingly showed that DLBCLs are de-
rived from germinal center B cells (GCB) or activated B
cells (ABC) [9–11]. Although the scientific evidence is ro-
bust and prognostically relevant, its translation into daily
practice remains impractical because of the required high
standard of tissue preservation, procedure duration, and
costs. This problem prompted the search for molecular
prognostic markers applicable to routine biopsies from pa-
tients with DLBCL. As a result, a large body of surrogate
(phenotypic) models and algorithms to identify GCB and
non-GCB DLBCL have been proposed and linked to out-
comes [12]. Unfortunately, reliability and reproducibility
of these models is often poor, impeding their translation
into standard practice to predict survival and stratify pa-
tients for risk-adjusted therapy [12–14]. Technical issues,
poor study designs, lack of standardization of evaluation
procedures, and, particularly, lack of prospective trials all
prevent an efficient clinical translation. A PubMed search
for “DLBCL,” “R-CHOP,” “prognostic,” “marker,” and
“prospective” identifies only a few prospective studies, in
which biomarkers have been considered (e.g., [15–24]).
Thus, there is an unmet requirement for further marker
validation in prospective trials.
The translational study of the clinical trial “SAKK 38/
07 Prospective evaluation of the prognostic value of
positron emission tomography (PET) in patients with
diffuse large B-cell-lymphoma under R-CHOP-14. A
multicenter study” offered a unique opportunity toprospectively analyze the prognostic and predictive value
of phenotypic and genotypic biomarkers suggested to
play a prognostic role in DLBCL on a well-documented
and homogenously treated clinical trial collective.
Materials and methods
Patient recruitment, selection, and treatment
The recruitment of patients for the SAKK 38/07 study
started in November 2007 and finished in June 2010.
Evaluation of the prognostic value of metabolic responses,
as assessed by early PET after two cycles of R-CHOP-14,
to identify a poor outcome patient subgroup was the main
objective. PET was performed before, after two cycles of
therapy, and at the end of treatment and was evaluated
according to a 5-point scoring system with a cutoff
determining positivity being set at 4 points (moderately
increased uptake compared with the liver) [25]. The pri-
mary endpoint was event-free survival (EFS) at 2 years,
and the secondary endpoints were progression-free
(PFS) and overall survival (OS) after 2 and 5 years as
well as the objective responses according to inter-
national criteria [26]. In accordance with the statistical
advice for reaching sufficient power to address the two
endpoints, recruitment of 154 patients was aimed. Be-
cause of concurrent registrations on the last recruit-
ment day, 156 instead of 154 patients were recruited.
Inclusion criteria were histologically proven diagnosis of
CD20-positive DLBCL (no pretreatment revision of the
slides by an expert hematopathologist was planned) in-
cluding all Ann Arbor stages, tumor size >14 mm on
CT or MRI (because lymph nodes ≥15 mm are consid-
ered “pathologic” on computerized imaging), PET posi-
tivity of the tumors (documented 2 weeks to 4 days
prior to registration), performance status 0–2 on the
ECOG scale, age >17, as well as no evidence of symp-
tomatic central nervous system (CNS) disease, HIV,
and/or hepatitis infection [27]. The study treatment
consisted of R-CHOP given for six cycles followed by
additional two applications of rituximab every 2 weeks
(R-CHOP-14). Additionally, G-CSF support was given.
The patients were asked to provide informed consent
for the study and, separately, for the translational re-
search. The primary pathology institutions were asked
to send representative paraffin blocks for translational
research after accomplishing the in-house diagnostic
procedures to the Institute of Pathology at the University
Hospital Basel. The study was approved by the Ethics
Committee Beider Basel. Details of the SAKK 38/07 study
are reported elsewhere [28].
In situ biomarker analysis
Immunohistochemical (bcl2, bcl6, c-myc, CD5, CD10,
CD95, CD168, cyclin E, FOXP1, GCET, LMO2, MUM1p,
pSTAT3) and in situ hybridization analyses [BCL2
Tzankov et al. Journal of Hematology & Oncology  (2015) 8:70 Page 3 of 11break apart probe (BAP), C-MYC BAP and C-MYC/IGH
double-fusion probe (DFP), and Epstein–Barr virus probe
(EBER)] were performed and correlated with clinico-
pathological parameters and clinical endpoints. Cell of
origin (COO) was determined according to the Tally algo-
rithm [29]. Additionally, selected cases were stained for
CD23, CD30, cyclin D1, D2, D3, Ki-67, p27, p63, and
SOX11 for specification of diagnosis. Reagent sources,
pretreatment and incubation conditions, and cutoff scores
are listed in Table 1. Immunohistochemical markers were
assessed by microscopic counting of positive cells/tumor
cells and were recorded in 5 % increments in the primary
statistical table. All cases were scored after training by at
least two observers (either AT, SM, or SD), and only
markers for which Cronbach’s alpha analysis suggested
good agreement between observers (alpha >0.75) were
considered for prognostic evaluation. Relevant cutoff
scores were either taken from the literature [29, 30] or
calculated applying receiver operating characteristic
(ROC) analysis [12]. Discrepancies in the results for
evaluated markers, which were almost exclusively due
to differential assessment of weak staining signals,
were discussed at a double-headed microscope and the
concordant result was considered. Fluorescence in situ
hybridization (FISH) was performed exactly as described
elsewhere [31]. All cases were FISH-scored twice (NL
and AT) with an excellent agreement (alpha = 1) between
both observers.Table 1 Applied biomarker panel
Marker Source/clone Pretreatment
bcl2 Ventana/Roche 790-4604 CC1 16′
bcl6 Ventana/Roche 760-4241 CC1 32′
c-myc Ventana/Roche 790-4628 CC1 92′
CD5 Ventana/Roche 790-4451 CC1 24′
CD10 Ventana/Roche 790-4506 CC1 24′
CD95 Leica NCL-FAS-310 PC 120 °C, 3′, citrate buffer pH 6
CD168 Leica NCL-CD168 CC1 extended 92′
Cyclin E Thermo MS-1060-S MW 98 °C, 30′, citrate buffer pH 6
FOXP1 Ventana/Roche 760-4611 CC1 16′
GCET Abcam Ab68889 CC1 32′
LMO2 Ventana/Roche 790-4368 CC1 32′
MUM1p Ventana/Roche 760-4529 CC1 24′
pSTAT3 Cell Signaling 9145 MW 98 °C, 30′, TEC buffer pH 8
BCL2 BAP Abbott/Vysis 07 J75-001 Exactly as described [31]
C-MYC BAP Abbott/Vysis 05 J91-001
MYC/IGH DFP Abbott/Vysis 05 J75-001
EBER Ventana/Roche 760-1209 According to the manufacturer’s p
For diagnostic purposes and to “subtract” CD3-positive T cells in CD5-positive DLBC
biomarkers sensu strictoStatistics
All statistical analyses were performed using the Statis-
tical Package of Social Sciences (IBM SPSS version 19.0,
Chicago, IL, USA) for Windows and reported applying
the REMARK guidelines [32]. The inter-observer agree-
ment was assessed using the Cronbach’s alpha reliability
analysis; an alpha value of >0.75 indicates very good
agreement. The Spearman rank correlation was used to
analyze relationships between biomarkers and clinical
and laboratory parameters; only correlations with a
rho ≥ ±0.300 were considered. The Mann–Whitney U
and Kruskal–Wallis tests were applied, where appropriate,
to identify quantitative differences between groups. The
prognostic performance of variables and determination of
optimal cutoff values (except those extracted from the
most recent literature) was assessed by ROC curve plot-
ting sensitivity versus 1-specificity with special consider-
ation of the respective area under the ROC (AUROC).
The optimal cutoff point was calculated using Youden’s
index (Y), denoting Y = sensitivity + specificity − 1, since
this method can be applied to find the optimal unbiased
cutoff value with the highest sensitivity and specificity
[12]. OS was measured from registration to death or last
follow-up, PFS from registration to relapse, death of any
cause, or to last follow-up, and EFS from registration
to relapse or death of any cause, initiation of any non-
protocol anticancer treatment because of lymphoma
symptoms or need of concomitant radiotherapy or toDilution Incubation Other Cutoff (AUROC or reference)
RTU 12′ 70 % [34, 46]
RTU 28′ 30 % [30]
RTU 16′, 37 °C 40 % [34, 46]
RTU 12′ 20 % (0.542)
RTU 16′ 20 % [29]
1:400 60′, 20 °C 1 % (0.613)
1:200 32′ Biotin blocker 10 % (0.536)
Amplification
1:20 Overnight, 4 °C 12 % (0.669)
RTU 12′ 50 % [45]
1:25 20′ 60 % [29]
RTU 16′ 30 % [29]
RTU 16′ 70 % [29]





L, CD3 and CD20 stainings were also performed, but these were not considered
Table 2 Basic patient characteristics
Age, median (range) 58 (18–81)
Gender, N (%) F 68 (55)
M 55 (45)






























Collecting institutions, N (%) University hospitals 33 (27)
Other hospitals 90 (73)
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mined using the Kaplan–Meier method, and differ-
ences were compared using the log-rank test. All
biomarkers of prognostic significance in univariable
models underwent multivariable analysis using the Cox
proportional hazards model in a two-step manner
since only that response criterion (either according to
international criteria or PET or combined PET/CT re-
sponse) with the highest relevance in an independent
first step Cox model, run without biomarkers, was consid-
ered and compared to the biomarkers in the second step.
All p values were two-sided and considered statistically
significant if <0.05. No adjustment for multiple testing
was applied for secondary analyses because they were
considered hypothesis generating and exploratory.
Results
Patients, case review, and clinico-pathologic characteristics
Nineteen patients refused a participation in the transla-
tional research part of the project. In 11 cases, no material
for translational research was present. Thus, 126 cases
were further studied: DLBCL diagnosis could not be con-
firmed in three of these cases by conventional morphology
and additional immunohistochemical evaluation (the final
diagnosis of marginal zone lymphoma was established in
two cases and one turned to be a blastoid mantle cell
lymphoma). Thus, the analysis was finally performed on
123 cases. Patient characteristics are given in Table 2. Sur-
vival data were complete for 116 patients.
Eighty-nine lymphomas were primary nodal or of
lymphoid tissue (including the mediastinum, the spleen,
and Waldeyer’s ring), while 34 were extranodal (most
commonly soft tissue, gastrointestinal tract, and bones).
Based on integrative analysis, 100 cases were shown to
be centroblastic DLBCL, five were immunoblastic DLBCL,
three were anaplastic DLBCL, six were unclassifiable, six
were primary mediastinal large B cell lymphomas (PMBL;
thereof, two were nodal DLBCL with morphologic and
phenotypic features of PMBL), two were T cell- and
histiocyte-rich B cell lymphomas (THRBCL), and one
was a lymphomatoid granulomatosis (LG) grade 3.
The study material consisted of 66 (54 %) lymphade-
nectomy specimens that were studied on tissue micro-
arrays (TMA) and 57 (46 %) cases with only small core
needle biopsy material available, which were considered
non-arrayable and were studied on conventional serial
sections. Arrayable cases were brought into a TMA for-
mat applying the 1-mm core needle as described [33].
In situ biomarkers
Immunohistochemistry was evaluable in all cases, while
FISH was successful in 82 (67 %) instances (Table 3,
Fig. 1a–d); importantly, cases in which FISH failed were
evenly distributed among arrayable lymphadenectomyspecimens and small core needle biopsy specimens but
were more commonly observed in tissues from certain
primary pathology institutions. Taking into consideration
the Tally algorithm, 81 cases (66 %) were classified as
non-GCB DLBCL, while 42 cases (34 %) were GCB
DLBCL; after excluding the PMBL, THRBCL, and LG,
there were 39 GCB and 75 non-GCB cases. BCL2 gene
breaks were observed in 7/82 cases (9 %); 6 of the 7
(86 %) rearranged cases were of the GCB type. Two
cases (all of the non-GCB type) showed BCL2 amplifica-
tions. C-MYC breaks were observed in 6/82 cases (8 %);
4 were of the GCB type. Of the C-MYC rearranged
cases, only 2 displayed C-MYC/IGH fusions, detectable
by both DFP and BAP and corresponding to t(8;14),
while C-MYC rearrangements were detectable only by
BAP in the other 4 cases and were thus assumed to have
occurred with alternative non-IGH C-MYC rearrangement
partners. “Genetic double-hit” cases with BCL2 and C-
MYC rearrangements were not observed.
Table 3 Immunohistochemical staining results
COO bcl2 c-myc CD5 CD95 CD168 Cyclin E FOXP1 pSTAT3 EBER
Evaluable cases 123 123 123 123 123 123 123 123 123 123
Mean % of stained cells ± SD na 34 ± 38 32 ± 26 2 ± 14 32 ± 42 4 ± 9 8 ± 13 31 ± 38 19 ± 27 na
N (%) above cutoff na 34 (28) 44 (36) 4 (3) 60 (48) 38 (31) 30 (24) 44 (36) 44 (36) 2 (1.5)
Mean % of stained cells ± SD in positive cases na 94 ± 10 61 ± 20 72 ± 27 65 ± 38 13 ± 13 26 ± 13 79 ± 17 49 ± 26 33 ± 25
Germinal center B cell (GCB) like, N (%) 42 (34) 11 (32)a 16 (36)a 1 (25)a 22 (37)a 18 (47)a 11 (37)a 8 (18)a 17 (39)a 1 (50)a
Except for FOXP1, which was of prognostic significance as an isolated marker, all other relevant proteins for cell of origin (COO) classification according to the
Tally algorithm are summarized within the COO column
na not applicable
aGCB out of the positive cases
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sion of bcl2 (rho = 0.355, p = 0.001), CD10 (rho = 0.388,
p < 0.005), and GCB (rho = 0.302, p = 0.006). As ex-
pected, expression of GCET, bcl6, CD10, and LMO2
correlated with each other (GCB COO). pSTAT3 corre-
lated with MUM1p, FOXP1, bcl6, and CD168 (rho =
0.301–0.473, p = 0.01–0.0001). FOXP1 correlated with
bcl2, MUM1p, and c-myc (rho = 0.429, 0.438, and 0.319,
respectively, p < 0.001). Expression of CD5 did not cor-
relate with any of the examined single variables but
showed a weak correlation with the so-called phenotypic
bcl2/c-myc double hits (rho = 0.24, p = 0.02). Phenotypic
bcl2/c-myc double hits [34] correlated with expression
of FOXP1 (rho = 0.379, p = 0.0002) and BCL2 rearrange-
ments (rho = 0.319, p = 0.005).Fig. 1 Microphotographs of selected cases. Co-expression of CD20 (a) and
lymphoma. Microphotographs have been taken from consecutive sections;
Original magnification × 320. c Expression of FOXP1 in a positive case. Orig
to a BCL2 gene rearrangement (translocation). Fused yellow signals correspoOutcome analysis
The primary study endpoint, i.e., EFS at 2 years, correlated
with failure to achieve response according to international
criteria and failure to achieve complete combined meta-
bolic and morphologic response or metabolic response
(rho values for all >0.470, p values for all <1e − 5). The me-
dian follow-up period was 53 months (95 % CI 45–51).
There were 48 events, including 16 lethal events and 12
relapses 3 months after achievement of CR, of which 6
occurred >12 months after initial diagnosis. The 16 lethal
events encompassed 9 deceases with/of disease and 7
deaths unrelated to cancer. Mean OS was 68 months (95 %
CI 64–71), mean PFS was 59 months (95 % CI 53–65), and
mean EFS was 46 months (95 % CI 40–52); median OS,
PFS, and EFS for the whole collective were not reached.CD5 (b) in an extranodal (intestinal) CD5-positive diffuse large B cell
note deeper sections in b of the same glandular structures from a.
inal magnification × 400. d Split red and green signals corresponding
nding to the non-translocated allele. Original magnification × 800
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portance after rational dichotomization (cutoffs listed in
Table 1). Factors able to predict worse EFS in univariate
Kaplan–Meier models were failure to achieve response
according to international criteria, failure to achieve
complete combined metabolic and morphologic response
or metabolic response (p values for all <0.005), expression
of CD5 (p = 0.02; Fig. 2a), and higher stage (p = 0.021).
Factors predicting inferior PFS were failure to achieve
response according to international criteria, failure to
achieve complete combined metabolic and morphologic
(but not only metabolic) response (p < 0.005), higher IPI
(p = 0.006), higher stage (p = 0.005), presence of either
C-MYC or BCL2 gene rearrangements (p = 0.033; Fig. 2b),
and expression of cyclin E in >12 % of tumor cells (p =
0.046; Fig. 2c). Finally, factors predicting inferior OS were
failure to achieve response according to international cri-
teria, failure to achieve complete combined metabolic and
morphologic (but not only metabolic) response (p values
for all <0.005), expression of FOXP1 in >50 % of tumor
cells (p < 0.005; Fig. 2d), expression of cyclin E in >12 % of
tumor cells (p = 0.005), expression of CD5 (p = 0.007),
expression of bcl2 in >70 % of tumor cells (p = 0.016),
expression of CD95 in any tumor cell (p = 0.018), and ex-
pression of pSTAT3 in >17 % of tumor cells (p = 0.025).
All other clinico-pathological and phenotypic variables
were not of prognostic significance respecting EFS, PFS,
and OS. The multivariable analyses’ results for EFS, PFS,
and OS are shown in Table 4. Subgroup analysis limited
to the DLBCL, not otherwise specified (NOS) cohortFig. 2 Survival curves. Event-free (EFS) (a), progression-free (PFS) (b, c), and(omitting PMBL, THRBCL, and LG because of their more
specific biology) revealed that expression of CD5 (p =
0.044) retained its independent prognostic significance
with respect to EFS (more sensitive for early events) and
expression of FOXP1 (p = 0.004) with respect to OS (later
events), while all other biomarkers failed to add prognostic
information. In the case of CD5 because of the only weak
correlation of CD5 with phenotypic bcl2/c-myc double
hits, the limited number of CD5-positive cases, and the
lacking prognostic significance of phenotypic bcl2/c-myc
double hits in that series, multivariable analysis was not
adjusted for phenotypic bcl2/c-myc double hits. Adjust-
ment for phenotypic bcl2/c-myc double-hit scores in the
case of FOXP1 showed that it retained its prognostic sig-
nificance in those DLBCL, NOS cases scored 0 and 1 (and
outperformed failure to achieve combined metabolic and
morphologic remission in cases scored 0), but neither
expression of FOXP1 nor failure to achieve complete
combined metabolic and morphologic remission were
of prognostic significance with respect to OS in pheno-
typic bcl2/c-myc double-hit score 2 DLBCL, NOS cases
(data not shown in detail).
Since CD5 expression appeared to be of significant rele-
vance, we thoroughly revised the four CD5-positive cases
and evaluated multiple immunohistochemical markers to
exclude blastoid mantle cell lymphomas (shown above).
The four CD5-positive DLBCL were negative for cyclin
D1 and SOX11 and expressed p27. These cases stained
positively for CD5 in 50 to 100 % of tumor cells did not
show an intravascular component and were negative foroverall survival (OS) (d) with respect to biomarker expression
Table 4 Multivariable analysis
Survival Parameter Hazard ratio 95 % CI p value
Event-free Lack of complete combined metabolic and morphologic remission 2.54 1.84–3.51 <0.005
Expression of CD5 2.99 1.02–9.13 0.047
Progression-free Lack of complete remission according to international criteria 16.39 4.57–58.82 <0.005
Overall Expression of FOXP1 5.61 1.34–23.4 0.018
Lack of complete combined metabolic and morphologic remission 1.93 1.04–3.58 0.038
Only significant results are shown
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GCB; and three showed centroblastic morphology, while
one was classified as centroblastic with increased immuno-
blasts. None of these four CD5-positive cases showed
presence of either C-MYC or BCL2 gene rearrangements;
however, two patients fulfilled phenotypic criteria for
double-hit lymphoma, expressing bcl2 or c-myc above the
respective cutoff scores. Two patients were male; two suf-
fered from nodal lymphomas; two were Ann Arbor stage
II, while the other two were stage I and III, respectively;
and two patients had an IPI of 1 and two an IPI of 2. The
mean age of the CD5-positive patients was 64 ± 13 years,
while that of the CD5-negative was 58 ± 13 (difference not
of statistical significance). Two of the four patients failed
to achieve remission (one of these two patients died of/
with lymphoma) and in the other two DLBCL relapsed
after 8 and 38 months, respectively. Finally, DNA of the
four CD5-positive cases was extracted and subjected to
array comparative genomic hybridization (aCGH) analysis
(Fig. 3) exactly as described elsewhere [35]. The analysis
was successful in two cases and showed recurrent gains of
19q and losses of 1q43 [36], thus further corroborating
the diagnosis of DLBCL. One of the cases showed specific
loss of 9p21 (INK4A locus, also known as p16) known to
be associated with DLBCL resistance to R-CHOP [37].Fig. 3 Copy number aberrations in a CD5-positive case. Only aberrant chro
of DNA. Darker red in the long arm of chromosome 18 indicates high-level
locus), known to be associated with chemoresistanceDiscussion
Within this prospective study, we identified potential
biomarkers (expression of CD5 for EFS and expression
of FOXP1 for OS) that were able to predict the course
of DLBCL at diagnosis, independent of stage and IPI. As
expected ([38] and literature therein), dynamic parameters,
such as response to therapy and especially failure to
achieve complete remission, which are not obtainable at
diagnosis, seem to be the most reliable outcome indicators
in DLBCL, yet expression of CD5 and FOXP1 added infor-
mation independent of these disease dynamic parameters.
Concerning the central aim of our study, i.e., to detect
in situ biomarkers that reliably help predicting the
outcome of DLBCL in a prospective, homogeneously
treated collective of patients, our phenotypic and geno-
typic analyses show that carefully selected indicators
such as CD5 might identify small yet prognostically rele-
vant subgroups with adverse outcomes under R-CHOP.
CD5 as biomarker has a special sensitivity towards early
adverse events, which might not be the case for some of
the currently propagated biomarkers of prognostic rele-
vance such as c-myc expression/C-MYC gene status.
Furthermore, our data reappraise the prognostic role of
FOXP1 with respect to OS. Several other previously
studied biomarkers with suspected prognostic potentialmosomes are shown. Green represents losses, and red represents gains
amplification of this region. Note the small deletion at 9p21.3 (INK4A
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score appeared to be less potent in the studied collective.
This might in part be due to the small size of our study,
in part to genuine properties of these markers, and in
part to the fact that some of these markers, while being
applicable to CHOP-treated DLBCL patients, are not ap-
plicable to cases treated with R-CHOP [39]. Considering
our study size, there are obvious and inevitable limita-
tions. Yet, because of the other characteristics of our
collective (123 uniformly treated patients with a median
follow-up period of 53 months and altogether 51 adverse
events), our data solidifies understanding of the prognostic
importance of in situ biomarkers in DLBLC and the 2-year
EFS analysis delivers important results. Respecting the
genuine properties of some markers, especially those used
as surrogates to determine COO, our results as well as
observations of others [14] seriously challenge their reli-
ability to identify prognostically and/or biologically mean-
ingful groups among DLBCL.
Our observed prognostic role of CD5 and FOXP1 and
possible prognostic role of bcl2 as well as structural genetic
aberrations of (either) BCL2 or C-MYC are supported by
other reports ([31, 40–46] and literature therein). While a
considerable number of recent papers focused on the role
of bcl2 and c-myc in DLBCL [34, 46, 47], it seems that
CD5 merits special attention for several reasons: (a) it can
be very easily detected in DLBCL by standard application
of CD5 (instead of CD3) immunohistochemistry in the pri-
mary diagnostic panel with subsequent application of CD3
in CD5-positive cases (to subtract the “true” T cells), as
well as CD23, cyclin D1, and SOX11 (to exclude trans-
formed small lymphocytic B cell lymphomas and blastoid
mantle cell lymphomas); (b) the respective cases express
CD5 in a high proportion of tumor cells (>50–100 %) with
a moderate to strong staining intensity, and thus, its evalu-
ation is unequivocal without the need for subjective and
error-prone cutoff scores; and (c) because there is an in-
creasing body of literature suggesting that CD5-positive
DLBCL might represent a distinct biologic entity, being
more prone to intravascular spread and extranodal loca-
tion (particularly CNS), affecting individuals from the
Far East and displaying a more aggressive behavior
probably requiring alternative treatment approaches [40].
CD5-positive DLBCL are typically ABC [42, 48], show re-
current gains of 16p and losses of 1p and of 9q21 [36, 49],
the latter being involved in chemoresistance [37], and dis-
play downregulation of extracellular matrix-related genes
and upregulation of neurological function-related genes
[48]. Addition of rituximab to CHOP improved the sur-
vival of CD5-positive DLBCL patients [50]; however, simi-
larly to our results, the outcome of these patients is still
significantly poorer compared to CD5-negative DLBCL
patients [51], and the rate of CNS involvement seems not
to be lowered by rituximab [52]. A recent very largeretrospective report on 879 R-CHOP-treated DLBCL
cases convincingly showed CD5 to be an IPI (and bcl2
and pSTAT3)-independent prognosticator in DLBCL as
well [53] and pointed out distinct clinico-pathological pe-
culiarities of such patients such as increased age, bone
marrow spread, poor performance status, and B symp-
toms. Considering the possible direct biological effect of
CD5 on B cells, namely its role as a negative regulator of
B cell signaling, its influence on the ERK, PI3K, and cal-
cineurin pathways as well as survival stimulation through
autocrine IL10-related loops and the predominant expres-
sion of integrin beta-1 on the tumor cells, CD5 seems to
be of probable functional and therapeutic importance for
targeted approaches [40, 54–56]. In addition, CD5-positive
cases seem to overexpress bcl2, CARD11, CCND2, and
FOXP1 at the protein and mRNA level and to be more rich
in c-Rel, p65, and pSTAT3 [53], all known to identify
DLBCL patients at risk; this study [53] also confirmed [48]
downregulation of cellular adhesion genes in such in-
stances. Taken together, previous data and our observa-
tions might justify a separation of CD5-positive DLBCL
out of the group of DLBCL, NOS, as a distinct clinico-
pathological entity in need of R-CHOP treatment alterna-
tives and, probably, CNS prophylaxis.
The prognostic role of FOXP1 in DLBCL was well
established in the “pre-rituximab” era ([45] and references
therein), while less attention has been paid to it in R-
CHOP-treated cases. Importantly, prognostically relevant
COO algorithms pay special attention towards expression
of FOXP1 to classify non-GCB-like DLBCL and >90 %
concordance with GEP was only achievable by consider-
ation of FOXP1 in these algorithms (e.g., [29, 44]). In line
with these results, the recent report on the very poor prog-
nosis of DLBCL reciprocally expressing the endocytic pro-
tein Huntingtin-interacting protein 1-related (HIP1R) and
FOXP1 (the latter being a direct repressor of the HIP1R
gene), i.e., FOXP1(hi)/HIP1R(lo) patients [57], and our
prospective study findings suggest a more substantial
relevance of FOXP1 in DLBCL. Importantly, FOXP1 be-
longs to the most reproducibly assessable markers in
DLBCL as shown in an international inter- and intra-
institutional and inter- and intra-observer study [58], fur-
ther calling for its regular evaluation.
Unexpectedly, a significant (33 % for FISH and 50 % for
aCGH) dropout of cases for genotypic studies was noted.
Detailed analysis of these cases revealed that pre-analytic
conditions like inappropriate application of un-buffered
formalin, fixation duration, surrounding temperature, and
exact dehydration procedures were probably more rele-
vant for lack of analytic success than the exact amount of
examined tissue. Indeed, these failures were evenly distrib-
uted between core needle biopsies and lymphadenectomy
specimens but were more commonly observed among tis-
sues from a few centers. As expected, diagnostic tissue
Tzankov et al. Journal of Hematology & Oncology  (2015) 8:70 Page 9 of 11obtained by core needle biopsy procedures (usually 14–
18G needles) was not arrayable and was rapidly exhausted
for purposes of the study, precluding further analyses.
Since cohorts of prospective clinical trials are character-
ized by meticulous documentation and uniform treatment
of patients (the latter, if not uniform, can more substan-
tially affect disease prognosis than many biomarkers), bio-
marker analyses should desirably be performed on cases
collected within such studies. Therefore, the amount and
the pre-analytical handling of tissue required for study in-
clusion must be considered also under the aspect of bio-
marker analyses. This particularly implies that physicians
obtaining and handling the respective biopsies as well as
the pathology laboratories must take responsibility for
error-free and safe pre-analytic conduits, guaranteeing op-
timal tissue fixation and dehydration, which are indispens-
able for an accurate morphologic, phenotypic, and genetic
analysis. For practical purposes, the protocol for probe
handling from the laboratory, which provided probes with
least dropout on molecular testing, is given in Additional
file 1: Table S1.Conclusions
In summary, distinct biomarkers like CD5 and FOXP1
are able to prognosticate DLBCL course at diagnosis, in-
dependent of stage and IPI and independent of initial
therapy response. For the design of prospective DLBCL
studies, issues like review of the slides by a central path-
ology, pre-analytic factors such as time to and time of
fixation, choice of fixative, and dehydration as well as
handling of biological entities and sub-entities in the
spectrum of aggressive large B cell lymphomas should
be properly discussed and promptly addressed.Additional file
Additional file 1: Table S1. Summary of pre-analytics in the lab,
submitting probes with least number of molecular testing dropouts.
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